{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:05:55Z","timestamp":1784073955773,"version":"3.55.0"},"reference-count":178,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:00:00Z","timestamp":1773187200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"vor","delay-in-days":126,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Patient Rep Outcomes"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Acromegaly is a rare disease caused by a pituitary adenoma in most cases. Physical changes, metabolic disturbances, osteoarticular symptoms, as well as psychological and social repercussions reduce the Quality of Life (QoL) of people suffering from the disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To assess both generic and disease-specific instruments employed to capture the influence of acromegaly on patients\u2019 QoL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>This scoping review assessed the different tools used to evaluate QoL in people with acromegaly. This review followed the methods proposed by the Joanna Briggs Institute and is reported following the Preferred Reporting Items for Systematic Reviews manual and Meta-Analyses extension for Scoping Reviews.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of a total of 198 studies, 30 questionnaires were identified and categorized by type (specific or generic) and number of domains assessed (physical health, psychological state, autonomy, and social relationships). Among these, 3 were specific-multidomain, 18 generic-multidomain, 3 specific-unidomain, 5 generic-unidomain, and only 1 had no domains. All were patient-reported outcome measures (PROM) used in various contexts. Optimal instruments were disease-specific, multidimensional, brief, easily administered, available in multiple languages, with psychometric validation in acromegaly patients and cross-cultural validation, and assessing treatment impact on QoL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This review explores the use of PROMs in assessing HRQoL in acromegaly patients, emphasizing the need for specific, validated, and culturally adapted tools addressing symptoms and treatment impact. We propose a novel domain-based classification to overcome existing limitations of instruments and improve their presentation in future studies. This study provides a synthesis that helps advance research and guide clinical practices around HRQoL in acromegaly management.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s41687-026-01022-3","type":"journal-article","created":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T08:34:16Z","timestamp":1773218056000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Quality of life questionnaires in patients with acromegaly: a scoping review"],"prefix":"10.1186","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2418-6159","authenticated-orcid":false,"given":"Carlos E.","family":"Builes-Monta\u00f1o","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0187-8232","authenticated-orcid":false,"given":"Jorge Eduardo","family":"Contreras-Saldarriaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0136-2567","authenticated-orcid":false,"given":"Oriana","family":"Arroyo-Ripoll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8581-2267","authenticated-orcid":false,"given":"Jorge Hernando","family":"Donado-Gomez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,11]]},"reference":[{"key":"1022_CR1","unstructured":"Fleseriu M, Langlois F, Lim DST, Varlamov E V, Melmed S (2022 Oct) Acromegaly: pathogenesis, diagnosis, and management. Lancet Diabetes Endocrinol; S2213-8587(22)00244-3"},{"issue":"1","key":"1022_CR2","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/s41572-019-0071-6","volume":"5","author":"A Colao","year":"2019","unstructured":"Colao A, Grasso LFS, Giustina A, Melmed S, Chanson P, Pereira AM et al (2019 Dec 1) Acromegaly. Nat Rev Dis Primers 5(1):20","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"1022_CR3","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1159\/000375450","volume":"103","author":"KMJA Claessen","year":"2016","unstructured":"Claessen KMJA, Mazziotti G, Biermasz NR, Giustina A (2016 Feb 1) Bone and joint disorders in acromegaly. Neuroendocrinology 103(1):86\u201395","journal-title":"Neuroendocrinology"},{"issue":"4","key":"1022_CR4","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.ecl.2022.04.004","volume":"51","author":"EC Coopmans","year":"2022","unstructured":"Coopmans EC, Andela CD, Claessen KMJA, Biermasz NR (2022 Dec) Evaluating the impact of acromegaly on quality of life. Endocrinol Metab Clin N Am 51(4):709\u2013725","journal-title":"Endocrinol Metab Clin N Am"},{"issue":"5","key":"1022_CR5","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1007\/s11102-014-0626-1","volume":"18","author":"KT Kimmell","year":"2015","unstructured":"Kimmell KT, Weil RJ, Marko NF (2015 Oct 10) Multi-modal management of acromegaly: a value perspective. Pituitary 18(5):658\u2013665","journal-title":"Pituitary"},{"issue":"1","key":"1022_CR6","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.ecl.2014.10.013","volume":"44","author":"I Crespo","year":"2015","unstructured":"Crespo I, Valassi E, Santos A, Webb SM (2015 Mar 1) Health-related quality of life in pituitary diseases. Endocrinol Metab Clin N Am 44(1):161\u2013170","journal-title":"Endocrinol Metab Clin N Am"},{"key":"1022_CR7","doi-asserted-by":"crossref","unstructured":"Crespo I, Valassi E, Webb SM Update on quality of life in patients with acromegaly. Pituit 2016, 20: 1 20(1):185\u2013188. 2016 Oct 11","DOI":"10.1007\/s11102-016-0761-y"},{"issue":"5","key":"1022_CR8","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1007\/s11102-015-0636-7","volume":"18","author":"CD Andela","year":"2015","unstructured":"Andela CD, Scharloo M, Pereira AM, Kaptein AA, Biermasz NR (2015 Oct 10) Quality of life (QoL) impairments in patients with a pituitary adenoma: a systematic review of QoL studies. Pituitary 18(5):752\u2013776","journal-title":"Pituitary"},{"key":"1022_CR9","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.2147\/PPA.S102302","volume":"10","author":"EA Christofides","year":"2016","unstructured":"Christofides EA (2016 Jul 13) Clinical importance of achieving biochemical control with medical therapy in adult patients with acromegaly. Patient Prefer Adherence 10:1217\u20131225","journal-title":"Patient Prefer Adherence"},{"key":"1022_CR10","unstructured":"Giustina A (2016 Aug 1) Acromegaly: reducing diagnostic delay. Recenti Prog Med [Internet]. 107(8):450\u2013451. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/27571562\/. cited 2022 Nov 6"},{"issue":"5","key":"1022_CR11","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.3390\/jcm10051147","volume":"10","author":"A Akirov","year":"2021","unstructured":"Akirov A, Masri-Iraqi H, Dotan I, Shimon I (2021) The biochemical diagnosis of acromegaly. J Clin Med 10(5):1147","journal-title":"J Clin Med"},{"issue":"6","key":"1022_CR12","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1530\/EJE-20-0019","volume":"182","author":"D Esposito","year":"2020","unstructured":"Esposito D, Ragnarsson O, Johannsson G, Olsson DS (2020 Jun 1) Prolonged diagnostic delay in acromegaly is associated with increased morbidity and mortality. Eur J Endocrinol 182(6):523\u2013531","journal-title":"Eur J Endocrinol"},{"key":"1022_CR13","doi-asserted-by":"crossref","unstructured":"Ioachimescu AG (2021 Aug 1) Acromegaly: achieving timely diagnosis and improving outcomes by personalized care. Curr Opin Endocrinol Diabetes Obes [Internet]. cited 2022 Nov 6. 28(4):419\u2013426. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/34101652\/","DOI":"10.1097\/MED.0000000000000650"},{"issue":"4","key":"1022_CR14","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.rdc.2010.09.004","volume":"36","author":"Z Killinger","year":"2010","unstructured":"Killinger Z, Payer J, Laz\u00farov\u00e1 I, Imrich R, Hom\u00e9rov\u00e1 Z, Ku\u017ema M et al (2010 Nov) Arthropathy in acromegaly. Rheum Dis Clin N Am 36(4):713\u2013720","journal-title":"Rheum Dis Clin N Am"},{"key":"1022_CR15","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/978-90-481-9485-8_15","volume":"686","author":"L Rajmil","year":"2010","unstructured":"Rajmil L, Perestelo-P\u00e9rez L, Herdman M (2010) Quality of life and rare diseases. Adv Exp Med Biol 686:251\u2013272","journal-title":"Adv Exp Med Biol"},{"issue":"5","key":"1022_CR16","doi-asserted-by":"publisher","first-page":"402","DOI":"10.4103\/ijem.IJEM_401_20","volume":"24","author":"de Oliveira Ba","year":"2020","unstructured":"de Oliveira Ba, Ara\u00fajo, Santos Tm D, Ongaratti BR, Le\u00e3es Rech, Ferreira NP et al (2020 Sep 1) Health-related quality of life in acromegaly patients: results from generic and disease-specific questionnaires. Indian J Endocrinol Metab 24(5):402\u2013405","journal-title":"Indian J Endocrinol Metab"},{"key":"1022_CR17","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/1477-7525-2-13","volume":"2","author":"X Badia","year":"2004","unstructured":"Badia X, Webb SM, Prieto L, Lara N (2004 Feb 27) Acromegaly quality of life questionnaire (AcroQol). Health Qual Life Outcomes 2:13","journal-title":"Health Qual Life Outcomes"},{"key":"1022_CR18","doi-asserted-by":"crossref","unstructured":"Guo X, Wang K, Yu S, Gao L, Wang Z, Zhu H et al (2021 Jan 1) Quality of life and its determinants in patients with treated acromegaly: a cross-sectional nationwide study in China. J Clin Endocrinol Metab [Internet]. cited 2023 Dec 28. 106(1):211\u2013225. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/33079177\/","DOI":"10.1210\/clinem\/dgaa750"},{"key":"1022_CR19","doi-asserted-by":"crossref","unstructured":"Andela CD, Scharloo M, Ramondt S, Tiemensma J, Husson O, Llahana S et al (2016 Jun 1) The development and validation of the leiden Bother and Needs questionnaire for patients with pituitary disease: the LBNQ-Pituitary. Pituitary [Internet]. 19(3):293\u2013302. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/26809957\/. cited 2023 Dec 28","DOI":"10.1007\/s11102-016-0707-4"},{"key":"1022_CR20","doi-asserted-by":"crossref","unstructured":"Fujio S, Arimura H, Hirano H, Habu M, Bohara M, Moinuddin FM et al (2017) Changes in quality of life in patients with acromegaly after surgical remission - a prospective study using SF-36 questionnaire. Endocr J [Internet]. 64(1):27\u201338. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/27681883\/. cited 2022 Nov 6","DOI":"10.1507\/endocrj.EJ16-0182"},{"issue":"2","key":"1022_CR21","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1046\/j.1365-2265.2002.01597.x","volume":"57","author":"SM Webb","year":"2002","unstructured":"Webb SM, Prieto L, Badia X, Albareda M, Catal\u00e1 M, Gaztambide S et al (2002) Acromegaly quality of life questionnaire (ACROQOL) a new health-related quality of life questionnaire for patients with acromegaly: development and psychometric properties. Clin Endocrinol (Oxf) 57(2):251\u2013258","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"5","key":"1022_CR22","first-page":"293","volume":"31","author":"P Gayoso Diz","year":"2003","unstructured":"Gayoso Diz P (2003 Mar 30) Commentary: importance of health-related quality of life in primary care. Aten Primaria 31(5):293\u2013294","journal-title":"Aten Primaria"},{"issue":"1","key":"1022_CR23","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1001\/jama.1995.03520250075037","volume":"273","author":"IB Wilson","year":"1995","unstructured":"Wilson IB, Cleary PD (1995 Jan 4) Linking clinical Variables with health-related quality of life: a conceptual model of patient outcomes. JAMA 273(1):59\u201365","journal-title":"JAMA"},{"issue":"1","key":"1022_CR24","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s11136-008-9413-7","volume":"18","author":"KN Lohr","year":"2009","unstructured":"Lohr KN, Zebrack BJ (2009 Feb) Using patient-reported outcomes in clinical practice: challenges and opportunities. Qual Life Res 18(1):99\u2013107","journal-title":"Qual Life Res"},{"issue":"1","key":"1022_CR25","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1159\/000375451","volume":"103","author":"SM Webb","year":"2016","unstructured":"Webb SM, Badia X (2016 Feb 1) Quality of life in acromegaly. Neuroendocrinology 103(1):106\u2013111","journal-title":"Neuroendocrinology"},{"key":"1022_CR26","doi-asserted-by":"publisher","first-page":"101389","DOI":"10.1016\/j.ghir.2021.101389","volume":"59","author":"MD Whittington","year":"2021","unstructured":"Whittington MD, Munoz KA, Whalen JD, Ribeiro-Oliveira A, Campbell JD (2021 Aug 1) Economic and clinical burden of comorbidities among patients with acromegaly. Growth Hormone IGF Res 59:101389","journal-title":"Growth Hormone IGF Res"},{"issue":"1","key":"1022_CR27","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1080\/1364557032000119616","volume":"8","author":"H Arksey","year":"2005","unstructured":"Arksey H, O\u2019Malley L (2005 Feb) Scoping studies: towards a methodological framework. Int J Soc Res Methodol 8(1):19\u201332","journal-title":"Int J Soc Res Methodol"},{"issue":"3","key":"1022_CR28","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1097\/XEB.0000000000000050","volume":"13","author":"MDJ Peters","year":"2015","unstructured":"Peters MDJ, Godfrey CM, Khalil H, McInerney P, Parker D, Soares CB (2015 Sep 1) Guidance for conducting systematic scoping reviews. Int J Evid Based Healthc 13(3):141\u2013146","journal-title":"Int J Evid Based Healthc"},{"issue":"7","key":"1022_CR29","doi-asserted-by":"publisher","first-page":"467","DOI":"10.7326\/M18-0850","volume":"169","author":"AC Tricco","year":"2018","unstructured":"Tricco AC, Lillie E, Zarin W, Kk O, Colquhoun H, Levac D et al (2018) PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med 169(7):467\u2013473","journal-title":"Ann Intern Med"},{"issue":"5","key":"1022_CR30","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1016\/S0149-2918(96)80054-3","volume":"18","author":"KN Lohr","year":"1996","unstructured":"Lohr KN, Aaronson NK, Alonso J, Burnam MA, Patrick DL, Perrin EB et al (1996 Sep 1) Evaluating quality-of-life and health status instruments: development of scientific review criteria. Clin Ther 18(5):979\u2013992","journal-title":"Clin Ther"},{"key":"1022_CR31","doi-asserted-by":"crossref","unstructured":"Prinsen CAC, Mokkink LB, Bouter LM, Alonso J, Patrick DL, de Vet HCW et al (2018 May 1) COSMIN guideline for systematic reviews of patient-reported outcome measures. Qual Life Res [Internet]. 27(5):1147\u20131157. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/29435801\/. cited 2024 Jan 27","DOI":"10.1007\/s11136-018-1798-3"},{"key":"1022_CR32","doi-asserted-by":"crossref","unstructured":"Liberati A, Altman DG, Tetzlaff J, Mulrow C, G\u00f8tzsche PC, Ioannidis JPA et al (2009 Oct 1) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol [Internet]. 62(10):e1\u201334. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/19631507\/. cited 2024 Jan 12","DOI":"10.1016\/j.jclinepi.2009.06.006"},{"key":"1022_CR33","doi-asserted-by":"crossref","unstructured":"Cesnales NI, Thyer BA (2014 [cited 2024 Jan 12]. Health-related quality of life measures. Encycl Qual Life Well-Being Res [Internet]. 2809\u20132814. Available from: https:\/\/link.springer.com\/referenceworkentry\/10.1007\/978-94-007-0753-5_951","DOI":"10.1007\/978-94-007-0753-5_951"},{"key":"1022_CR34","doi-asserted-by":"crossref","unstructured":"Trainer PJ, Drake WM, Katznelson L, Freda PU, Herman-Bonert V, van der Lely AJ et al (2000 Apr 20) Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med [Internet]. 342(16):1171\u20131177. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/10770982\/. cited 2023 Dec 27","DOI":"10.1056\/NEJM200004203421604"},{"key":"1022_CR35","doi-asserted-by":"crossref","unstructured":"Fleseriu M, Fogelfeld L, Gordon MB, Sisco J, Colwell HH, Ludlam WH et al (2019 Dec 1) Development of a novel patient-reported measure for acromegaly: the Acro-TSQ. Pituitary [Internet]. 22(6):581\u2013593. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/31522359\/. cited 2023 Dec 27","DOI":"10.1007\/s11102-019-00986-4"},{"issue":"5","key":"1022_CR36","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1055\/s-0030-1267912","volume":"119","author":"T Psaras","year":"2011","unstructured":"Psaras T, Honegger J, Gallwitz B, Milian M (2011) Are there gender-specific differences concerning quality of life in treated acromegalic patients? Exp Clin Endocrinol Diabetes 119(5):300\u2013305","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"1022_CR37","doi-asserted-by":"crossref","unstructured":"Rowles S V, Prieto L, Badia X, Shalet SM, Webb SM, Trainer PJ (2005 Jun) Quality of life (QOL) in patients with acromegaly is severely impaired: use of a novel measure of QOL: acromegaly quality of life questionnaire. J Clin Endocrinol Metab [Internet]. 90(6):3337\u20133341. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/15755865\/. cited 2023 Dec 27","DOI":"10.1210\/jc.2004-1565"},{"key":"1022_CR38","doi-asserted-by":"crossref","unstructured":"Lenderking WR, Zacker C, Katznelson L, Vance ML, Hossain S, Tafesse E et al (2000) The reliability and validity of the impact on lifestyle questionnaire in patients with acromegaly. Value Health [Internet]. 3(4):261\u2013269. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/16464190\/. cited 2023 Dec 27","DOI":"10.1046\/j.1524-4733.2000.34003.x"},{"key":"1022_CR39","unstructured":"McNair DM, Lorr M, Droppleman LF (1971) EITS manual for the profile of mood States. San Diego, CA: Educational and Industrial Testing Service"},{"key":"1022_CR40","doi-asserted-by":"crossref","unstructured":"Horne R, Weinman J, Hankins M (1999) The beliefs about medicines questionnaire: the development and evaluation of a new method for assessing the cognitive representation of medication. Psychol Health [Internet]. 14(1):1\u201324. Available from: https:\/\/www.tandfonline.com\/doi\/abs\/10.1080\/08870449908407311. cited 2023 Dec 28","DOI":"10.1080\/08870449908407311"},{"key":"1022_CR41","doi-asserted-by":"crossref","unstructured":"Moss-Morris R, Weinman J, Petrie K, Horne R, Cameron L, Buick D (2002 Feb) The revised illness perception questionnaire (IPQ-R). Psychol Health [Internet]. 17(1):1\u201316. Available from: https:\/\/www.tandfonline.com\/doi\/abs\/10.1080\/08870440290001494. cited 2023 Dec 28","DOI":"10.1080\/08870440290001494"},{"issue":"10","key":"1022_CR42","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","volume":"20","author":"M Herdman","year":"2011","unstructured":"Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D et al (2011 Dec) Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res 20(10):1727\u20131736","journal-title":"Qual Life Res"},{"key":"1022_CR43","doi-asserted-by":"crossref","unstructured":"Folsten MF, Luria R (1973) Reliability, validity, and clinical application of the visual Analogue mood scale. Psychol Med [Internet]. 3(4):479\u2013486. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/4762224\/. cited 2023 Dec 28","DOI":"10.1017\/S0033291700054283"},{"key":"1022_CR44","unstructured":"Schwarzer R, Jerusalem M (1995 Dec) Measures in health psychology: a User\u2019s portfolio. Causal and control beliefs. Causal Control Beliefs 1:35\u201337"},{"key":"1022_CR45","doi-asserted-by":"crossref","unstructured":"Cardol M, De Haan RJ, Van Den Bos GAM, De Jong BA, De Groot IJM (1999) The development of a handicap assessment questionnaire: the impact on participation and autonomy (IPA). Clin Rehabil [Internet]. 13(5):411\u2013419. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/10498348\/. cited 2023 Dec 28","DOI":"10.1191\/026921599668601325"},{"key":"1022_CR46","unstructured":"Scheurs P, Van de Willige G, Brosschot J, Tellegen B, Graus G De Utrechtse coping lijst: UCL. Swets en Zeitlinger b.v, Lisse, The Netherlands"},{"key":"1022_CR47","doi-asserted-by":"crossref","unstructured":"Ware JE, Sherbourne CD (1992 Jun) The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 30(6):473\u2013483","DOI":"10.1097\/00005650-199206000-00002"},{"key":"1022_CR48","doi-asserted-by":"crossref","unstructured":"Smets EMA, Garssen B, Bonke B, De Haes JCJM (1995) The multidimensional fatigue inventory (MFI) psychometric qualities of an instrument to assess fatigue. J Psychosom Res [Internet]. 39(3):315\u2013325. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/7636775\/. cited 2023 Dec 28","DOI":"10.1016\/0022-3999(94)00125-O"},{"key":"1022_CR49","doi-asserted-by":"crossref","unstructured":"Zigmond AS, Snaith RP (1983) The hospital anxiety and depression scale. Acta Psychiatr Scand [Internet]. 67(6):361\u2013370. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/6880820\/. cited 2023 Dec 28","DOI":"10.1111\/j.1600-0447.1983.tb09716.x"},{"key":"1022_CR50","doi-asserted-by":"crossref","unstructured":"Krupp LB, Larocca NG, Muir Nash J, Steinberg AD (1989) The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol [Internet]. 46(10):1121\u20131123. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/2803071\/. cited 2023 Dec 28","DOI":"10.1001\/archneur.1989.00520460115022"},{"key":"1022_CR51","doi-asserted-by":"crossref","unstructured":"Bharmal M, Payne K, Atkinson MJ, Desrosiers MP, Morisky DE, Gemmen E (2009 Apr 27) Validation of an abbreviated Treatment Satisfaction Questionnaire for Medication (TSQM-9) among patients on antihypertensive medications. Health Qual Life Outcomes [Internet]. [cited 2023 Dec 28]:7. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/19397800\/","DOI":"10.1186\/1477-7525-7-36"},{"key":"1022_CR52","doi-asserted-by":"crossref","unstructured":"Hunt SM, McEwen J (1980 Nov) The development of a subjective health indicator. Sociol Health Illn [Internet]. 2(3):231\u2013246. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/10298135\/. cited 2023 Dec 28","DOI":"10.1111\/1467-9566.ep11340686"},{"issue":"12","key":"1022_CR53","first-page":"1833","volume":"15","author":"N Bellamy","year":"1988","unstructured":"Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW (1988 Dec) Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol 15(12):1833\u20131840","journal-title":"J Rheumatol"},{"key":"1022_CR54","doi-asserted-by":"crossref","unstructured":"Meenan RF, Gertman PM, Mason JH (1980) Measuring health status in arthritis. The arthritis impact measurement scales. Arthritis Rheum [Internet]. 23(2):146\u2013152. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/7362665\/. cited 2023 Dec 28","DOI":"10.1002\/art.1780230203"},{"key":"1022_CR55","doi-asserted-by":"crossref","unstructured":"Hays RD, Morales LS (2001) The RAND-36 measure of health-related quality of life. Ann Med [Internet]. 33(5):350\u2013357. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/11491194\/. cited 2023 Dec 28","DOI":"10.3109\/07853890109002089"},{"key":"1022_CR56","doi-asserted-by":"crossref","unstructured":"Kan P, Cusimano M (2006) Validation of a quality-of-life questionnaire for patients with pituitary adenoma. Can J Neurol Sci [Internet]. 33(1):80\u201385. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/16583727\/. cited 2023 Dec 28","DOI":"10.1017\/S0317167100004741"},{"key":"1022_CR57","doi-asserted-by":"crossref","unstructured":"Harper A, Power M, Orley J, Herrman H, Schofield H, Murphy B et al (1998 May) Development of the world health Organization WHOQOL-BREF quality of life assessment. The WHOQOL group. Psychol Med [Internet]. 28(3):551\u2013558. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/9626712\/. cited 2023 Dec 28","DOI":"10.1017\/S0033291798006667"},{"key":"1022_CR58","doi-asserted-by":"crossref","unstructured":"Wenger NK, Mattson ME, Furberg CD, Elinson J (1984 Oct 1) Assessment of quality of life in clinical trials of cardiovascular therapies. Am J Cardiol [Internet]. 54(7):908\u2013913. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/6333175\/. cited 2023 Dec 28","DOI":"10.1016\/S0002-9149(84)80232-5"},{"key":"1022_CR59","first-page":"51","volume-title":"Abridged manual of the symptom questionnaire","author":"R Kellner","year":"1976","unstructured":"Kellner R (1976) Abridged manual of the symptom questionnaire. University of New Mexico, Albuquerque, pp 51\u201353"},{"key":"1022_CR60","doi-asserted-by":"crossref","unstructured":"De Waal MWM, Arnold IA, Spinhoven P, Eekhof JAH, Van Hemert AM (2005 Aug) The reporting of specific physical symptoms for mental distress in general practice. J Psychosom Res [Internet]. 59(2):89\u201395. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/16186004\/. cited 2023 Dec 28","DOI":"10.1016\/j.jpsychores.2005.02.011"},{"key":"1022_CR61","doi-asserted-by":"crossref","unstructured":"Sintonen H (2001) The 15D instrument of health-related quality of life: properties and applications. Ann Med [Internet]. cited 2023 Dec 28. 33(5):328\u2013336. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/11491191\/","DOI":"10.3109\/07853890109002086"},{"key":"1022_CR62","doi-asserted-by":"crossref","unstructured":"Danaei M, Bahadorizadeh L, Dehnad A, Mohamadzadeh S, Hashemi-Madani N, Khamseh ME (2022 Dec 1) Validation of acromegaly quality of life questionnaire (AcroQol) for the Iranian population. BMC Psychol 10(1)","DOI":"10.1186\/s40359-022-00781-0"},{"key":"1022_CR63","doi-asserted-by":"crossref","unstructured":"Hua SC, Yan YH, Chang TC (2006 Dec) Associations of remission status and lanreotide treatment with quality of life in patients with treated acromegaly. Eur J Endocrinol [Internet]. 155(6):831\u2013837. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/17132752\/. cited 2023 Dec 28","DOI":"10.1530\/eje.1.02292"},{"key":"1022_CR64","doi-asserted-by":"crossref","unstructured":"Anagnostis P, Efstathiadou ZA, Charizopoulou M, Selalmatzidou D, Karathanasi E, Poulasouchidou M et al (2014 Oct 21) Psychological profile and quality of life in patients with acromegaly in Greece. Is there any difference with other chronic diseases? Endocrine [Internet]. 47(2):564\u2013571. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/24510628\/. cited 2023 Dec 28","DOI":"10.1007\/s12020-014-0166-5"},{"key":"1022_CR65","doi-asserted-by":"crossref","unstructured":"Biermasz NR, Van Thiel SW, Pereira AM, Hoftijzer HC, Van Hemert AM, Smit JWA et al (2004 Nov) Decreased quality of life in patients with acromegaly despite long-term cure of growth hormone excess. J Clin Endocrinol Metab [Internet]. 89(11):5369\u20135376. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/15531483\/. cited 2023 Dec 28","DOI":"10.1210\/jc.2004-0669"},{"key":"1022_CR66","unstructured":"Celik O, Kadioglu P (2013 Jun) Quality of life in female patients with acromegaly. J Endocrinol Invest [Internet]. 36(6):412\u2013416. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/23211278\/. cited 2023 Dec 28"},{"key":"1022_CR67","doi-asserted-by":"crossref","unstructured":"Geraedts VJ, Dimopoulou C, Auer M, Schopohl J, Stalla GK, Sievers C (2015 [cited 2024 Jan 3];Health outcomes in acromegaly: depression and anxiety are promising targets for improving reduced quality of life. Front endocrinol (Lausanne) [Internet]. 5(DEC). Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/25610427\/","DOI":"10.3389\/fendo.2014.00229"},{"key":"1022_CR68","doi-asserted-by":"crossref","unstructured":"Herman R, Gori\u010dar K, Jane\u017e A, Jensterle M (2022 Jul 1) Clinical applicability of patient- and Clinician-reported outcome tools in the management of patients with acromegaly. Endocr Pract [Internet]. 28(7):678\u2013683. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/35421593\/. cited 2023 Dec 28","DOI":"10.1016\/j.eprac.2022.04.002"},{"key":"1022_CR69","doi-asserted-by":"crossref","unstructured":"Jawiarczyk-Przyby\u0142owska A, Szcze\u015bniak D, Ciu\u0142kowicz M, Bolanowski M, Rymaszewska J (2020 Jan 14 [cited 2024 Jan 4]. Importance of illness acceptance among other factors affecting quality of life in acromegaly. Front endocrinol (Lausanne) [Internet]. 10. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/32010060\/","DOI":"10.3389\/fendo.2019.00899"},{"key":"1022_CR70","doi-asserted-by":"crossref","unstructured":"Kimball A, Dichtel LE, Yuen KCJ, Woodmansee WW, Haines MS, Nachtigall LB et al (2022 Jun 1) Quality of life after long-term biochemical control of acromegaly. Pituitary [Internet]. 25(3):531\u2013539. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/35476257\/. cited 2023 Dec 28","DOI":"10.1007\/s11102-022-01224-0"},{"key":"1022_CR71","doi-asserted-by":"crossref","unstructured":"Koby\u0142ko A, Szcze\u015bniak D, Halupczok-\u017by\u0142a J, Marciniak D, Jawiarczyk-Przyby\u0142owska A, Bolanowski M et al (2022 Aug 1 [cited 2023 Dec 28];The clinical complexity of patients with acromegaly. J Psychosom Res [Internet]. 159. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/35644085\/","DOI":"10.1016\/j.jpsychores.2022.110946"},{"key":"1022_CR72","doi-asserted-by":"crossref","unstructured":"Kyriakakis N, Lynch J, Gilbey SG, Webb SM, Murray RD (2017 Jun 1) Impaired quality of life in patients with treated acromegaly despite long-term biochemically stable disease: results from a 5-years prospective study. Clin Endocrinol (Oxf) [Internet]. 86(6):806\u2013815. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/28316090\/. cited 2023 Dec 28","DOI":"10.1111\/cen.13331"},{"key":"1022_CR73","doi-asserted-by":"crossref","unstructured":"Liu S, Adelman DT, Xu Y, Sisco J, Begelman SM, Webb SM et al (2018 Mar 1) Patient-centered assessment on disease burden, quality of life, and treatment satisfaction associated with acromegaly. J Investig Med [Internet]. 66(3):653\u2013660. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/29151042\/. cited 2023 Dec 28","DOI":"10.1136\/jim-2017-000570"},{"key":"1022_CR74","doi-asserted-by":"crossref","unstructured":"Felt JM, Depaoli SA, Pereira AM, Biermasz NR, Tiemensma J (2015 Jul 1) Total score or subscales in scoring the acromegaly quality of life questionnaire: using novel confirmatory methods to compare scoring options. Eur J Endocrinol [Internet]. 173(1):37\u201342. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/25872514\/. cited 2023 Dec 28","DOI":"10.1530\/EJE-15-0228"},{"key":"1022_CR75","unstructured":"Cangiano B, Giusti E, Premoli C, Soranna D, Vitale G, Grottoli S et al (2022 Sep 1) Psychological complications in patients with acromegaly: relationships with sex, arthropathy, and quality of life. Endocrine [Internet]. 77(3):510\u2013518. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/35779206\/. cited 2023 Dec 28"},{"key":"1022_CR76","doi-asserted-by":"crossref","unstructured":"Dal J, Rosendal C, Karmisholt J, Feldt-Rasmussen U, Andersen MS, Klose M et al (2023 Jan 1) Sex difference in patients with controlled acromegaly-A multicentre survey. Clin Endocrinol (Oxf) [Internet]. 98(1):74\u201381. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/35474467\/. cited 2023 Dec 28","DOI":"10.1111\/cen.14750"},{"key":"1022_CR77","doi-asserted-by":"crossref","unstructured":"Arshad MF, Ogunleye O, Ross R, Debono M (2021 Oct 1) Surgically treated acromegaly patients have a similar quality of life whether controlled by surgery or requiring additional medical therapy (QuaLAT study). Pituitary 24(5):768\u2013777","DOI":"10.1007\/s11102-021-01153-4"},{"key":"1022_CR78","doi-asserted-by":"crossref","unstructured":"Bernab\u00e9u I, Fajardo C, Marazuela M, Cordido F, Venegas EM, de Pablos-Velasco P et al (2020 Dec 1) Effectiveness of lanreotide autogel 120 mg at extended dosing intervals for acromegaly. Endocrine [Internet]. 70(3):575\u2013583. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/32725444\/. cited 2023 Dec 28","DOI":"10.1007\/s12020-020-02424-z"},{"key":"1022_CR79","doi-asserted-by":"crossref","unstructured":"Bolanowski M, Hubalewska-Dydejczyk A, Kos-Kud\u0142a B, Rucha\u0142a M, Witek P, Zgliczy\u0144ski W et al (2021 Oct 29) Quality of life in patients with acromegaly receiving lanreotide autogel: a real-world observational study. Endokrynol Pol [Internet]. 72(5):512\u2013519. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/34647602\/. cited 2023 Dec 28","DOI":"10.5603\/EP.a2021.0075"},{"key":"1022_CR80","doi-asserted-by":"crossref","unstructured":"Chin SO, Chung CH, Chung YS, Kim BJ, Kim HY, Kim IJ et al (2015) Change in quality of life in patients with acromegaly after treatment with octreotide LAR: first application of AcroQoL in Korea. BMJ Open [Internet]. 5(6). Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/26063564\/. cited 2023 Dec 28","DOI":"10.1136\/bmjopen-2014-006898"},{"key":"1022_CR81","doi-asserted-by":"crossref","unstructured":"Coopmans EC, El-Sayed N, Frystyk J, Magnusson NE, J\u00f8rgensen JOL, van der Lely AJ et al (2020 Jul 1) Soluble Klotho: a possible predictor of quality of life in acromegaly patients. Endocrine [Internet]. 69(1):165\u2013174. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/32333268\/. cited 2023 Dec 28","DOI":"10.1007\/s12020-020-02306-4"},{"key":"1022_CR82","doi-asserted-by":"crossref","unstructured":"Dichtel LE, Kimball A, Yuen KCJ, Woodmansee W, Haines MS, Guan QX et al (2021 Jan 1) Effects of growth hormone receptor antagonism and somatostatin analog administration on quality of life in acromegaly. Clin Endocrinol (Oxf) [Internet]. 94(1):58\u201365. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/32779234\/. cited 2023 Dec 28","DOI":"10.1111\/cen.14309"},{"key":"1022_CR83","doi-asserted-by":"crossref","unstructured":"Mangupli R, Camperos P, Webb SM (2014 Nov 7) Biochemical and quality of life responses to octreotide-LAR in acromegaly. Pituitary [Internet]. 17(6):495\u2013499. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/24178448\/. cited 2023 Dec 28","DOI":"10.1007\/s11102-013-0533-x"},{"key":"1022_CR84","unstructured":"Caglar E, Hatipoglu E, Niyazoglu M, Celik O, Tuncer M, Kadioglu P (2013) Acromegaly is not associated with irritable bowel syndrome: a pilot study. Neuro Endocrinol Lett 34(1):71\u201374"},{"key":"1022_CR85","doi-asserted-by":"crossref","unstructured":"Cannav\u00f2 S, Condurso R, Ragonese M, Ferra\u00f9 F, Alibrandi A, Aric\u00f2 I et al (2011 Dec) Increased prevalence of restless legs syndrome in patients with acromegaly and effects on quality of life assessed by Acro-QoL. Pituitary [Internet]. 14(4):328\u2013334. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/21328081\/. cited 2023 Dec 28","DOI":"10.1007\/s11102-011-0298-z"},{"key":"1022_CR86","doi-asserted-by":"crossref","unstructured":"Cellini M, Biamonte E, Mazza M, Trenti N, Ragucci P, Milani D et al (2021 Jul 1) Vertebral fractures associated with spinal sagittal imbalance and quality of life in acromegaly: a radiographic study with EOS 2D\/3D technology. Neuroendocrinology [Internet]. 111(8):775\u2013785. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/32980840\/. cited 2023 Dec 28","DOI":"10.1159\/000511811"},{"key":"1022_CR87","doi-asserted-by":"crossref","unstructured":"Fatti LM, Cangiano B, Vitale G, Persani L, Mantovani G, Sala E et al (2019 Oct 1) Arthropathy in acromegaly: a questionnaire-based estimation of motor disability and its relation with quality of life and work productivity. Pituitary [Internet]. 22(5):552\u2013560. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/31032537\/. cited 2023 Dec 28","DOI":"10.1007\/s11102-019-00966-8"},{"key":"1022_CR88","doi-asserted-by":"crossref","unstructured":"Chen Z, Yu Y, He M, Shen M, Gong W, Wang M et al (2019 Jun 1) Higher growth hormone levels are associated with erectile dysfunction in male patients with acromegaly. Endocr Pract [Internet]. 25(6):562\u2013571. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/30865541\/. cited 2024 Jan 3","DOI":"10.4158\/EP-2018-0518"},{"key":"1022_CR89","doi-asserted-by":"crossref","unstructured":"Lima TRL, Kasuki L, Gadelha M, Lopes AJ (2019 Nov 1) Physical exercise improves functional capacity and quality of life in patients with acromegaly: a 12-week follow-up study. Endocrine [Internet]. 66(2):301\u2013309. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/31317523\/. cited 2024 Jan 3","DOI":"10.1007\/s12020-019-02011-x"},{"key":"1022_CR90","doi-asserted-by":"crossref","unstructured":"Lima TRL, Kasuki L, Gadelha MR, Lopes AJ (2019 Jul 1) The effectiveness of a therapist-oriented home rehabilitation program for a patient with acromegaly: a case study. J Bodyw Mov Ther [Internet]. 23(3):634\u2013642. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/31563382\/. cited 2024 Jan 3","DOI":"10.1016\/j.jbmt.2019.01.006"},{"key":"1022_CR91","doi-asserted-by":"crossref","unstructured":"Andela CD, Biermasz NR, Kaptein AA, Pereira AM, Tiemensma J (2015 Oct 1) More concerns and stronger beliefs about the necessity of medication in patients with acromegaly are associated with negative illness perceptions and impairment in quality of life. Growth Horm IGF Res [Internet]. 25(5):219\u2013226. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/26164770\/. cited 2024 Jan 3","DOI":"10.1016\/j.ghir.2015.06.008"},{"key":"1022_CR92","doi-asserted-by":"crossref","unstructured":"Kepicoglu H, Hatipoglu E, Bulut I, Darici E, Hizli N, Kadioglu P (2014 Nov 7) Impact of treatment satisfaction on quality of life of patients with acromegaly. Pituitary [Internet]. 17(6):557\u2013563. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/24337714\/. cited 2024 Jan 3","DOI":"10.1007\/s11102-013-0544-7"},{"key":"1022_CR93","doi-asserted-by":"crossref","unstructured":"S\u00f6zen M, K\u00f6se \u00d6, \u00c7etinarslan B, Cant\u00fcrk Z, Selek A, Demirhan Y et al (2023 Aug 1) The acromegaly treatment satisfaction questionnaire (Acro-TSQ): Turkish adaptation, validity, and reliability study. Pituitary [Internet]. 26(4):429\u2013436. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/37294511\/. cited 2024 Jan 7","DOI":"10.1007\/s11102-023-01323-6"},{"key":"1022_CR94","doi-asserted-by":"crossref","unstructured":"Fleseriu M, Fogelfeld L, Gordon MB, Sisco J, Crosby RD, Ludlam WH et al (2020 Aug 1) An evaluation of the acromegaly treatment satisfaction questionnaire (Acro-TSQ) in adult patients with acromegaly, including correlations with other patient-reported outcome measures: data from two large multicenter international studies. Pituitary [Internet]. 23(4):347\u2013358. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/32221764\/. cited 2024 Jan 3","DOI":"10.1007\/s11102-020-01038-y"},{"key":"1022_CR95","doi-asserted-by":"crossref","unstructured":"Fleseriu M, Molitch M, Dreval A, Biermasz NR, Gordon MB, Crosby RD et al (2021 Mar 15) Disease and treatment-related burden in patients with acromegaly who are biochemically controlled on injectable somatostatin receptor ligands. Front Endocrinol (Lausanne) 12","DOI":"10.3389\/fendo.2021.627711"},{"key":"1022_CR96","doi-asserted-by":"crossref","unstructured":"Geer EB, Sisco J, Adelman DT, Ludlam WH, Haviv A, Liu S et al (2020 Jul 31) Patient reported outcome data from acromegaly patients treated with injectable somatostatin receptor ligands (SRLs) in routine clinical practice. BMC Endocr Disord 20(1)","DOI":"10.1186\/s12902-020-00595-4"},{"key":"1022_CR97","doi-asserted-by":"crossref","unstructured":"Geer EB, Sisco J, Adelman DT, Ludlam WH, Haviv A, Gelbaum D et al (2020 Apr 1) Observed discordance between outcomes reported by acromegaly patients and their treating endocrinology medical provider. Pituitary [Internet]. 23(2):140\u2013148. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/31808101\/. cited 2024 Jan 3","DOI":"10.1007\/s11102-019-01013-2"},{"key":"1022_CR98","doi-asserted-by":"crossref","unstructured":"Ware JE, Kosinski M, Keller SD (1996) A 12-item Short-form health survey: construction of scales and preliminary tests of reliability and validity. Med Care [Internet]. 34(3):220\u2013233. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/8628042\/. cited 2024 Jan 3","DOI":"10.1097\/00005650-199603000-00003"},{"key":"1022_CR99","doi-asserted-by":"crossref","unstructured":"Wyrwich KW, Yu H (2011 Sep) Validation of POMS questionnaire in postmenopausal women. Qual Life Res [Internet]. 20(7):1111\u20131121. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/21279447\/. cited 2024 Jan 3","DOI":"10.1007\/s11136-011-9846-2"},{"key":"1022_CR100","doi-asserted-by":"crossref","unstructured":"Baker F, Denniston M, Zabora J, Polland A, Dudley WN (2002 Jul) A POMS short form for cancer patients: psychometric and structural evaluation. Psychooncology [Internet]. 11(4):273\u2013281. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/12203741\/. cited 2024 Jan 3","DOI":"10.1002\/pon.564"},{"key":"1022_CR101","doi-asserted-by":"crossref","unstructured":"Thomas SG, Woodhouse LJ, Pagura SM, Ezzat S (2002) Ventilation threshold as a measure of impaired physical performance in adults with growth hormone excess. Clin Endocrinol (Oxf) [Internet]. 56(3):351\u2013358. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/11940047\/. cited 2024 Jan 3","DOI":"10.1046\/j.1365-2265.2002.01476.x"},{"key":"1022_CR102","doi-asserted-by":"crossref","unstructured":"Fischer M, Scharloo M, Abbink J, Van\u2019t Hul A, Van Ranst D, Rudolphus A et al (2010 Nov [cited 2024 Jan 3];The dynamics of illness perceptions: testing assumptions of Leventhal\u2019s common-sense model in a pulmonary rehabilitation setting. Br J Health Psychol [Internet]. 15(Pt 4):887\u2013903. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/20230660\/","DOI":"10.1348\/135910710X492693"},{"key":"1022_CR103","doi-asserted-by":"crossref","unstructured":"Hirsch D, Ginat M, Levy S, Benbassat C, Weinstein R, Tsvetov G et al (2009) Illness perception in patients with differentiated epithelial cell thyroid cancer. Thyroid [Internet]. 19(5):459\u2013465. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/19415995\/. cited 2024 Jan 3","DOI":"10.1089\/thy.2008.0360"},{"key":"1022_CR104","doi-asserted-by":"crossref","unstructured":"Callaghan B, Condie E, Johnston M (2008) Using the common sense self-regulation model to determine psychological predictors of prosthetic use and activity limitations in lower limb amputees. Prosthet Orthot Int [Internet]. 32(3):324\u2013336. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/18825576\/. cited 2024 Jan 3","DOI":"10.1080\/03093640802242326"},{"key":"1022_CR105","doi-asserted-by":"crossref","unstructured":"Searle A, Norman P, Thompson R, Vedhara K (2007 Nov [cited 2024 Jan 3];A prospective examination of illness beliefs and coping in patients with type 2 diabetes. Br J Health Psychol [Internet]. 12(Pt 4):621\u2013638. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/17931477\/","DOI":"10.1348\/135910706X164935"},{"key":"1022_CR106","doi-asserted-by":"crossref","unstructured":"Tiemensma J, Kaptein AA, Pereira AM, Smit JWA, Romijn JA, Biermasz NR (2011 Nov) Affected illness perceptions and the association with impaired quality of life in patients with long-term remission of acromegaly. J Clin Endocrinol Metab [Internet]. 96(11):3550\u20133558. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/21917873\/. cited 2024 Jan 3","DOI":"10.1210\/jc.2011-1645"},{"key":"1022_CR107","doi-asserted-by":"crossref","unstructured":"Tiemensma J, Pereira AM, Romijn JA, Broadbent E, Biermasz NR, Kaptein AA (2015 May 1) Persistent negative illness perceptions despite long-term biochemical control of acromegaly: novel application of the drawing test. Eur J Endocrinol [Internet]. 172(5):583\u2013593. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/25724922\/. cited 2024 Jan 3","DOI":"10.1530\/EJE-14-0996"},{"key":"1022_CR108","unstructured":"EuroQol-a new facility for the measurement of health-related quality of life. Health Policy [Internet]. 199016(3):199\u2013208. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/10109801\/. cited 2024 Jan 3"},{"key":"1022_CR109","doi-asserted-by":"crossref","unstructured":"Kim SH, Kim HJ, Il LS, Jo MW (2012 Aug) Comparing the psychometric properties of the EQ-5D-3L and EQ-5D-5L in cancer patients in Korea. Qual Life Res [Internet]. 21(6):1065\u20131073. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/21947656\/. cited 2024 Jan 3","DOI":"10.1007\/s11136-011-0018-1"},{"key":"1022_CR110","doi-asserted-by":"crossref","unstructured":"Hurst NP, Kind P, Ruta D, Hunter M, Stubbings A (1997 May) Measuring health-related quality of life in rheumatoid arthritis: validity, responsiveness and reliability of EuroQol (EQ-5D). Br J Rheumatol [Internet]. 36(5):551\u2013559. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/9189057\/. cited 2024 Jan 3","DOI":"10.1093\/rheumatology\/36.5.551"},{"key":"1022_CR111","doi-asserted-by":"crossref","unstructured":"Bharmal M, Thomas J (2006) Comparing the EQ-5D and the SF-6D descriptive systems to assess their ceiling effects in the US general population. Value Health [Internet]. 9(4):262\u2013271. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/16903996\/. cited 2024 Jan 3","DOI":"10.1111\/j.1524-4733.2006.00108.x"},{"key":"1022_CR112","doi-asserted-by":"crossref","unstructured":"Aggarwal R, Wilke CT, Pickard AS, Vats V, Mikolaitis R, Fogg L et al (2009 Jun) Psychometric properties of the EuroQol-5D and Short form-6D in patients with systemic lupus erythematosus. J Rheumatol [Internet]. 36(6):1209\u20131216. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/19369452\/. cited 2024 Jan 3","DOI":"10.3899\/jrheum.081022"},{"key":"1022_CR113","doi-asserted-by":"crossref","unstructured":"Kunz S (2010 Apr) Psychometric properties of the EQ-5D in a study of people with mild to moderate dementia. Qual Life Res [Internet]. cited 2024 Jan 3. 19(3):425\u2013434. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/20146008\/","DOI":"10.1007\/s11136-010-9600-1"},{"key":"1022_CR114","doi-asserted-by":"crossref","unstructured":"Mercier-Juttier H, Novella JL, Carr\u00e9-Pigeon F, Chaunu MP, Gaillard D, Boyer F (2006 Apr) Psychometric properties of the Euroqol measure in patients with muscular dystrophy. Ann Readapt Med Phys [Internet]. 49(3):105\u2013112. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/16488048\/. cited 2024 Jan 26","DOI":"10.1016\/j.annrmp.2006.01.007"},{"key":"1022_CR115","doi-asserted-by":"crossref","unstructured":"Bilbao A, Mart\u00edn-Fern\u00e1ndez J, Garc\u00eda-P\u00e9rez L, Mendezona JI, Arrasate M, Candela R et al (2022) Psychometric properties of the EQ-5D-5L in patients with major depression: factor analysis and Rasch analysis. J Ment Health [Internet]. 31(4):506\u2013516. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/33522336\/. cited 2024 Jan 3","DOI":"10.1080\/09638237.2021.1875422"},{"key":"1022_CR116","doi-asserted-by":"crossref","unstructured":"Paisley AN, Rowles S V, Roberts ME, Webb SM, Badia X, Prieto L et al (2007 Sep) Treatment of acromegaly improves quality of life, measured by AcroQol. Clin Endocrinol (Oxf) [Internet]. 67(3):358\u2013362. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/17555502\/. cited 2024 Jan 3","DOI":"10.1111\/j.1365-2265.2007.02891.x"},{"key":"1022_CR117","doi-asserted-by":"crossref","unstructured":"Lobatto DJ, Steffens ANV, Zamanipoor Najafabadi AH, Andela CD, Pereira AM, van den Hout WB et al (2018 Dec 1) Work disability and its determinants in patients with pituitary tumor-related disease. Pituitary [Internet]. 21(6):593\u2013604. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/30288666\/. cited 2024 Jan 3","DOI":"10.1007\/s11102-018-0913-3"},{"key":"1022_CR118","doi-asserted-by":"crossref","unstructured":"Andela CD, Repping-Wuts H, Stikkelbroeck NMML, Pronk MC, Tiemensma J, Hermus AR et al (2017 Jul 1) Enhanced self-efficacy after a self-management programme in pituitary disease: a randomized controlled trial. Eur J Endocrinol [Internet]. 177(1):59\u201372. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/28566534\/. cited 2024 Jan 3","DOI":"10.1530\/EJE-16-1015"},{"key":"1022_CR119","doi-asserted-by":"crossref","unstructured":"Cardol M, De Haan RJ, De Jong BA, Van den Bos GAM, De Groot IJM (2001) Psychometric properties of the impact on participation and autonomy questionnaire. Arch Phys Med Rehabil [Internet]. 82(2):210\u2013216. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/11239312\/. cited 2024 Jan 3","DOI":"10.1053\/apmr.2001.18218"},{"key":"1022_CR120","doi-asserted-by":"crossref","unstructured":"Van Der Klaauw AA, Kars M, Biermasz NR, Roelfsema F, Dekkers OM, Corssmit EP et al (2008 Nov) Disease-specific impairments in quality of life during long-term follow-up of patients with different pituitary adenomas. Clin Endocrinol (Oxf) [Internet]. 69(5):775\u2013784. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/18462264\/. cited 2024 Jan 4","DOI":"10.1111\/j.1365-2265.2008.03288.x"},{"key":"1022_CR121","doi-asserted-by":"crossref","unstructured":"Rotman M, Andela CD, Majoor BCJ, Dijkstra PDS, Hamdy NAT, Kaptein AA et al (2018 Nov 1) Passive coping strategies are associated with more impairment in quality of life in patients with fibrous dysplasia. Calcif Tissue Int [Internet]. 103(5):469\u2013475. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/29948062\/. cited 2024 Jan 3","DOI":"10.1007\/s00223-018-0441-1"},{"key":"1022_CR122","doi-asserted-by":"crossref","unstructured":"Turner H, Bryant-Waugh R, Peveler R, Bucks RS (2012 Jul) A psychometric evaluation of an English version of the Utrecht coping list. Eur Eat Disord Rev [Internet]. 20(4):339\u2013342. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/22419565\/. cited 2024 Jan 3","DOI":"10.1002\/erv.2173"},{"key":"1022_CR123","doi-asserted-by":"crossref","unstructured":"Ware JE (2000 Dec 15) SF-36 health survey update. Spine (Phila Pa 1976) [Internet]. cited 2024 Jan 3. 25(24):3130\u20133139. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/11124729\/","DOI":"10.1097\/00007632-200012150-00008"},{"key":"1022_CR124","doi-asserted-by":"crossref","unstructured":"Garratt A, Schmidt L, Mackintosh A, Fitzpatrick R (2002 Jun 15) Quality of life measurement: bibliographic study of patient assessed health outcome measures. BMJ [Internet]. 324(7351):1417\u20131419. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/12065262\/. cited 2024 Jan 3","DOI":"10.1136\/bmj.324.7351.1417"},{"key":"1022_CR125","doi-asserted-by":"crossref","unstructured":"Amjad F, Mohseni-Bandpei MA, Gilani SA, Ahmad A, Zaheer A (2022 Oct 1) Translation, cross-cultural adaptation, and psychometric properties of the Urdu version of Rand Short form 36-item survey (SF-36) among patients with lumbar radiculopathy. J Bodyw Mov Ther [Internet]. 32:176\u2013182. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/36180146\/. cited 2024 Jan 3","DOI":"10.1016\/j.jbmt.2022.05.003"},{"key":"1022_CR126","doi-asserted-by":"crossref","unstructured":"Witt S, Krauss E, Barbero MAN, M\u00fcller V, Bonniaud P, Vancheri C et al (2019 Mar 1) Psychometric properties and minimal important differences of SF-36 in idiopathic pulmonary fibrosis. Respir Res [Internet]. 20(1). Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/30823880\/. cited 2024 Jan 3","DOI":"10.1186\/s12931-019-1010-5"},{"key":"1022_CR127","doi-asserted-by":"crossref","unstructured":"Siegel S, Streetz-Van Der Werf C, Schott JS, Nolte K, Karges W, Kreitschmann-Andermahr I (2013 Dec) Diagnostic delay is associated with psychosocial impairment in acromegaly. Pituitary [Internet]. 16(4):507\u2013514. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/23179964\/. cited 2024 Jan 3","DOI":"10.1007\/s11102-012-0447-z"},{"key":"1022_CR128","doi-asserted-by":"crossref","unstructured":"Yamamoto N, Urai S, Fukuoka H, Yamamoto M, Yoshida K, Suzuki M et al (2022 Feb 3 [cited 2024 Jan 3];The effect of aging on quality of life in acromegaly patients under treatment. Front endocrinol (Lausanne) [Internet]. 13. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/35185799\/","DOI":"10.3389\/fendo.2022.819330"},{"key":"1022_CR129","doi-asserted-by":"crossref","unstructured":"Gagliardi I, Chiloiro S, Vallillo M, Bondanelli M, Volpato S, Giampietro A et al (2021 Dec 1) Multidimensional geriatric evaluation in acromegaly: a comparative cross-sectional study. BMC Geriatr [Internet]. 21(1). Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/34702173\/. cited 2024 Jan 3","DOI":"10.1186\/s12877-021-02549-4"},{"key":"1022_CR130","doi-asserted-by":"crossref","unstructured":"Vega-Beyhart A, Enriquez-Estrada VM, Bello-Chavolla OY, Torres-Victoria TR, Mart\u00ednez-S\u00e1nchez FD, L\u00f3pez-Navarro JM et al (2019 Mar 1) Quality of life is significantly impaired in both secretory and non-functioning pituitary adenomas. Clin Endocrinol (Oxf) [Internet]. 90(3):457\u2013467. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/30548674\/. cited 2024 Jan 3","DOI":"10.1111\/cen.13915"},{"key":"1022_CR131","doi-asserted-by":"crossref","unstructured":"Yoshida K, Fukuoka H, Matsumoto R, Bando H, Suda K, Nishizawa H et al (2015 Jun 30) The quality of life in acromegalic patients with biochemical remission by surgery alone is superior to that in those with pharmaceutical therapy without radiotherapy, using the newly developed Japanese version of the AcroQoL. Pituitary 18(6):876\u2013883","DOI":"10.1007\/s11102-015-0665-2"},{"key":"1022_CR132","doi-asserted-by":"crossref","unstructured":"Ferreira S, Sintonen H, Raimundo A, Batalha N, Mendoza-Mu\u00f1oz M, Perez-Gomez J et al (2023 Apr 1) Translation, cultural adaptation, and reliability of the 15D Portuguese version: a generic health-related quality of life (HRQoL) instrument. Healthcare (Basel) [Internet]. 11(8). Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/37107933\/. cited 2024 Jan 7","DOI":"10.3390\/healthcare11081099"},{"key":"1022_CR133","doi-asserted-by":"crossref","unstructured":"Raappana A, Piril\u00e4 T, Ebeling T, Salmela P, Sintonen H, Koivukangas J (2012 Dec 31) Long-term health-related quality of life of surgically treated pituitary adenoma patients: a descriptive study. ISRN Endocrinol [Internet]. 2012:1\u20138. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/23346413\/. cited 2024 Jan 7","DOI":"10.5402\/2012\/675310"},{"key":"1022_CR134","doi-asserted-by":"crossref","unstructured":"Camerini S, Wennberg A, Adriani M, Martin B, Vettor R, Maffei P et al (2022 Oct 1) Questionnaire and tools: clinical powerful instrument in acromegaly diagnosis and management. J Endocrinol Invest [Internet]. 45(10):1823\u20131834. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/35322391\/. cited 2022 Nov 6","DOI":"10.1007\/s40618-022-01782-x"},{"issue":"2","key":"1022_CR135","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1210\/clinem\/dgaa868","volume":"106","author":"LHA Broersen","year":"2021","unstructured":"Broersen LHA, Zamanipoor Najafabadi AH, Pereira AM, Dekkers OM, Van Furth WR, Biermasz NR (2021 Jan 23) Improvement in symptoms and health-related quality of life in acromegaly patients: a systematic review and meta-analysis. J Clin Endocrinol Metab 106(2):577\u2013587","journal-title":"J Clin Endocrinol Metab"},{"key":"1022_CR136","doi-asserted-by":"crossref","unstructured":"Bonapart IE, van Domburg R, ten Have SMTH, de Herder WW, Erdman RAM, Jamjl J et al (2005 Feb) The \u201cbio-assay\u201d quality of life might be a better marker of disease activity in acromegalic patients than serum total IGF-I concentrations. Eur J Endocrinol [Internet]. 152(2):217\u2013224. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/15745929\/. cited 2024 Jan 3","DOI":"10.1530\/eje.1.01838"},{"key":"1022_CR137","doi-asserted-by":"crossref","unstructured":"Sagan KP, Andrysiak-Mamos E, Tyburski E, Sagan LM, Syrenicz A (2021 May 1) Quality of life and sleep in patients with pituitary adenoma in relation to tumor type and compression of the optic chiasm. J Clin Med [Internet]. 10(9). Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/33926090\/. cited 2024 Jan 3","DOI":"10.3390\/jcm10091879"},{"key":"1022_CR138","doi-asserted-by":"crossref","unstructured":"Van Der Klaauw AA, Biermasz NR, Hoftijzer HC, Pereira AM, Romijn JA (2008 Jul) Previous radiotherapy negatively influences quality of life during 4 years of follow-up in patients cured from acromegaly. Clin Endocrinol (Oxf) [Internet]. 69(1):123\u2013128. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/18182092\/. cited 2024 Jan 3","DOI":"10.1111\/j.1365-2265.2007.03169.x"},{"key":"1022_CR139","doi-asserted-by":"crossref","unstructured":"Varewijck AJ, van der Lely AJ, Sjcmm N, Lamberts SWJ, Hofland LJ, Jamjl J (2014 Apr 2) In active acromegaly, IGF1 bioactivity is related to soluble Klotho levels and quality of life. Endocr Connect [Internet]. 3(2):85\u201392. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/24692508\/. cited 2024 Jan 3","DOI":"10.1530\/EC-14-0028"},{"key":"1022_CR140","doi-asserted-by":"crossref","unstructured":"van Trigt Vr, Pelsma ICM, Kroon HM, Pereira AM, van der Meulen C, Kloppenburg M et al (2022 Apr 1) Low prevalence of neuropathic-like pain symptoms in long-term controlled acromegaly. Pituitary [Internet]. 25(2):229\u2013237. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/34687408\/. cited 2024 Jan 3","DOI":"10.1007\/s11102-021-01190-z"},{"key":"1022_CR141","doi-asserted-by":"crossref","unstructured":"Inayet N, Hayat J, Bano G, Poullis A (2020 Jun 8) Gastrointestinal symptoms in acromegaly: a case control study. World J Gastrointest Pharmacol Ther [Internet]. 11(2):17\u201324. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/32550042\/. cited 2024 Jan 3","DOI":"10.4292\/wjgpt.v11.i2.17"},{"key":"1022_CR142","doi-asserted-by":"crossref","unstructured":"Miller A, Doll H, David J, Wass J (2008 May) Impact of musculoskeletal disease on quality of life in long-standing acromegaly. Eur J Endocrinol [Internet]. 158(5):587\u2013593. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/18426816\/. cited 2024 Jan 3","DOI":"10.1530\/EJE-07-0838"},{"key":"1022_CR143","doi-asserted-by":"crossref","unstructured":"Pelsma ICM, Kroon HM, van Trigt VR, Pereira AM, Kloppenburg M, Biermasz NR et al (2022 Aug 1) Clinical and radiographic assessment of peripheral joints in controlled acromegaly. Pituitary [Internet]. 25(4):622\u2013635. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/35726113\/. cited 2024 Jan 4","DOI":"10.1007\/s11102-022-01233-z"},{"key":"1022_CR144","doi-asserted-by":"crossref","unstructured":"Wassenaar MJE, Biermasz NR, Kloppenburg M, van der KAA, Tiemensma J, Smit JWA et al (2010 Jun) Clinical osteoarthritis predicts physical and psychological QoL in acromegaly patients. Growth Horm IGF Res [Internet]. 20(3):226\u2013233. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/20194043\/. cited 2024 Jan 4","DOI":"10.1016\/j.ghir.2010.02.003"},{"key":"1022_CR145","doi-asserted-by":"crossref","unstructured":"Kreitschmann-Andermahr I, Kohlmann J, Kleist B, Hirschfelder U, Buslei R, Buchfelder M et al (2018 May 1) Oro-dental pathologies in acromegaly. Endocrine [Internet]. 60(2):323\u2013328. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/29520625\/. cited 2024 Jan 4","DOI":"10.1007\/s12020-018-1571-y"},{"key":"1022_CR146","doi-asserted-by":"crossref","unstructured":"Johnson MD, Woodburn CJ, Lee Vance M (2003) Quality of life in patients with a pituitary adenoma. Pituitary [Internet]. 6(2):81\u201387. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/14703017\/. cited 2024 Jan 4","DOI":"10.1023\/B:PITU.0000004798.27230.ed"},{"key":"1022_CR147","doi-asserted-by":"crossref","unstructured":"Wexler T, Gunnell L, Omer Z, Kuhlthau K, Beauregard C, Graham G et al (2009) Growth hormone deficiency is associated with decreased quality of life in patients with prior acromegaly. J Clin Endocrinol Metab [Internet]. 94(7):2471\u20132477. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/19366847\/. cited 2024 Jan 4","DOI":"10.1210\/jc.2008-2671"},{"key":"1022_CR148","doi-asserted-by":"crossref","unstructured":"Zhang X, Li Y, Zhong Y, Wang Z (2022 Jun 10 [cited 2024 Jan 4];Variables associated with Body image concerns in acromegaly patients: a cross-sectional study. Front psychol [Internet]. 13. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/35756208\/","DOI":"10.3389\/fpsyg.2022.733864"},{"key":"1022_CR149","doi-asserted-by":"crossref","unstructured":"Atkinson MJ, Sinha A, Hass SL, Colman SS, Kumar RN, Brod M et al (2004 Feb 26 [cited 2024 Jan 4];Validation of a general measure of treatment satisfaction, the treatment satisfaction questionnaire for medication (TSQM), using a national panel study of chronic disease. Health qual life outcomes [Internet]. 2. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/14987333\/","DOI":"10.1186\/1477-7525-2-12"},{"key":"1022_CR150","doi-asserted-by":"crossref","unstructured":"Hunt SM, McKenna SP, McEwen J, Backett EM, Williams J, Papp E (1980) A quantitative approach to perceived health status: a validation study. J Epidemiol Community Health (1978) [Internet]. 34(4):281\u2013286. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/7241028\/. cited 2024 Jan 4","DOI":"10.1136\/jech.34.4.281"},{"issue":"5","key":"1022_CR151","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1002\/1529-0131(200110)45:5<453::AID-ART365>3.0.CO;2-W","volume":"45","author":"S McConnell","year":"2001","unstructured":"McConnell S, Kolopack P, Davis AM (2001 Oct) The Western Ontario and McMaster Universities osteoarthritis Index (WOMAC): a review of its utility and measurement properties. Arthritis Rheum 45(5):453\u2013461","journal-title":"Arthritis Rheum"},{"key":"1022_CR152","doi-asserted-by":"crossref","unstructured":"Fathalla H, Cusimano MD, Alsharif OM, Jing R (2014 Nov 4) Endoscopic transphenoidal surgery for acromegaly improves quality of life. Can J Neurol Sci [Internet]. 41(6):735\u2013741. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/25431207\/. cited 2024 Jan 4","DOI":"10.1017\/cjn.2014.106"},{"key":"1022_CR153","doi-asserted-by":"crossref","unstructured":"Hays RD, Sherbourne CD, Mazel RM (1993) The RAND 36-item health survey 1.0. Health Econ [Internet]. 2(3):217\u2013227. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/8275167\/. cited 2024 Jan 4","DOI":"10.1002\/hec.4730020305"},{"key":"1022_CR154","doi-asserted-by":"crossref","unstructured":"Lins-Kusterer L, Aguiar I, Santos-Lins LS, Lins-Rocha M, Aguiar CVN, Menezes MS et al (2022) Validation of the RAND 36-item health survey questionnaire in Brazil. Arq Gastroenterol [Internet]. 59(2):193\u2013197. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/35830028\/. cited 2024 Jan 4","DOI":"10.1590\/s0004-2803.202202000-36"},{"key":"1022_CR155","doi-asserted-by":"crossref","unstructured":"Ohlsson-Nevo E, Hiyoshi A, Nor\u00e9n P, M\u00f6ller M, Karlsson J (2021 Dec 1) The Swedish RAND-36: psychometric characteristics and reference data from the Mid-Swed health survey. J Patient Rep Outcomes [Internet]. 5(1). Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/34347192\/. cited 2024 Jan 4","DOI":"10.1186\/s41687-021-00331-z"},{"key":"1022_CR156","doi-asserted-by":"crossref","unstructured":"Wolters TLC, Roerink SHPP, Sterenborg RBTM, Wagenmakers MAEM, Husson O, Smit JWA et al (2020) The effect of treatment on quality of life in patients with acromegaly: a prospective study. Eur J Endocrinol [Internet]. 182(3):319\u2013331. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/31958318\/. cited 2024 Jan 4","DOI":"10.1530\/EJE-19-0732"},{"key":"1022_CR157","doi-asserted-by":"crossref","unstructured":"Espinoza I, Osorio P, Torrej\u00f3n MJ, Lucas-Carrasco R, Bunout D (2011 May) Validaci\u00f3n del cuestionario de calidad de vida (WHOQOL-BREF) en adultos mayores chilenos. Rev Med Chil [Internet]. 139(5):579\u2013586. Available from: http:\/\/www.scielo.cl\/scielo.php?script=sci_arttext&pid=S0034-98872011000500003&lng=es&nrm=iso&tlng=es. cited 2024 Jan 4","DOI":"10.4067\/S0034-98872011000500003"},{"key":"1022_CR158","doi-asserted-by":"crossref","unstructured":"Hanestad BR, Rust\u00f8en T, Knudsen \u00d8, Lerdal A, Wahl AK (2004) Psychometric properties of the WHOQOL-BREF questionnaire for the Norwegian general population. J Nurs Meas [Internet]. 12(2):147\u2013159. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/16092712\/. cited 2024 Jan 7","DOI":"10.1891\/jnum.2004.12.2.147"},{"key":"1022_CR159","unstructured":"Szcze\u015bniak DM, Jawiarczyk-Przyby\u0142owska A, Matusiak \u0141, Bolanowska A, Maciaszek J, Siemi\u0144ska M et al (2017 Oct 29) Is there any difference in acromegaly and other chronic disease in quality of life and psychiatric morbidity? Endokrynol Pol [Internet]. 68(5). Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/28879648\/. cited 2024 Jan 7"},{"key":"1022_CR160","doi-asserted-by":"crossref","unstructured":"Grossi E, Groth N, Mosconi P, Cerutti R, Pace F, Compare A et al (2006 Nov 14) Development and validation of the short version of the Psychological General Well-Being Index (PGWB-S). Health Qual Life Outcomes [Internet]. [cited 2024 Jan 25]:4. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/17105655\/","DOI":"10.1186\/1477-7525-4-88"},{"key":"1022_CR161","doi-asserted-by":"crossref","unstructured":"Benasi G, Fava GA, Rafanelli C (2020 Mar 1) Kellner\u2019s symptom questionnaire, a highly sensitive patient-reported outcome measure: systematic review of clinimetric properties. Psychother Psychosom [Internet]. 89(2):74\u201389. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/32050199\/. cited 2024 Jan 7","DOI":"10.1159\/000506110"},{"key":"1022_CR162","unstructured":"Kellner R (1987 Jul) A symptom questionnaire. J Clin Psychiatry 48(7):268\u2013274"},{"key":"1022_CR163","doi-asserted-by":"crossref","unstructured":"Sonino N, Scarpa E, Paoletta A, Fallo F, Boscaro M (1999) Slow-release lanreotide treatment in acromegaly: effects on quality of life. Psychother Psychosom [Internet]. 68(3):165\u2013167. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/10224516\/. cited 2024 Jan 7","DOI":"10.1159\/000012326"},{"key":"1022_CR164","doi-asserted-by":"crossref","unstructured":"Aletras VH, Kontodimopoulos N, Niakas DA, Vagia MG, Pelteki HJ, Karatzoglou GI et al (2009) Valuation and preliminary validation of the Greek 15D in a sample of patients with coronary artery disease. Value Health [Internet]. 12(4):574\u2013579. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/18980637\/. cited 2024 Jan 7","DOI":"10.1111\/j.1524-4733.2008.00462.x"},{"key":"1022_CR165","doi-asserted-by":"crossref","unstructured":"Gliga MC, Reti Z, Gliga C, Pascanu IM (2022 Dec 1) Associations between paraclinical parameters, symptoms and quality of life in patients with acromegaly: a cross sectional study. J Patient Rep Outcomes [Internet]. 6(1). Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/36577870\/. cited 2024 Jan 7","DOI":"10.1186\/s41687-022-00537-9"},{"key":"1022_CR166","doi-asserted-by":"crossref","unstructured":"Sievers C, Baur DM, Schwanke A, Buchfelder M, Droste M, Mann K et al (2015 Jul 30) Prediction of therapy response in acromegalic patients under pegvisomant therapy within the German ACROSTUDY cohort. Pituitary 18(6):916\u2013923","DOI":"10.1007\/s11102-015-0673-2"},{"key":"1022_CR167","doi-asserted-by":"crossref","unstructured":"Marazuela M, Blanco C, Bernabeu I, Menendez E, Villar R, Paja M et al (2022 Feb 1) Acromegaly disease activity according to ACRODAT\u00ae, a cross-sectional study in Spain: ACROVAL study. Endocrine [Internet]. 75(2):525\u2013536. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/34668173\/. cited 2024 Jan 7","DOI":"10.1007\/s12020-021-02900-0"},{"key":"1022_CR168","doi-asserted-by":"crossref","unstructured":"Salvatori R, Maffei P, Webb SM, Brue T, Loftus J, Valluri SR et al (2022 Jun 1) Patient-reported outcomes in patients with acromegaly treated with pegvisomant in the ACROSTUDY extension: a real-world experience. Pituitary [Internet]. 25(3):420\u2013432. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/35022929\/. cited 2024 Jan 7","DOI":"10.1007\/s11102-022-01206-2"},{"key":"1022_CR169","doi-asserted-by":"crossref","unstructured":"Caron PJ, Bevan JS, Petersenn S, Houchard A, Sert C, Webb SM (2016 Apr 1) Effects of lanreotide autogel primary therapy on symptoms and quality-of-life in acromegaly: data from the PRIMARYS study. Pituitary 19(2):149\u2013157","DOI":"10.1007\/s11102-015-0693-y"},{"key":"1022_CR170","doi-asserted-by":"crossref","unstructured":"Neggers SJCMM, Van Aken MO, De Herder WW, Feelders RA, Janssen JAMJL, Badia X et al (2008) Quality of life in acromegalic patients during long-term somatostatin analog treatment with and without pegvisomant. J Clin Endocrinol Metab 93(10):3853\u20133859","DOI":"10.1210\/jc.2008-0669"},{"key":"1022_CR171","doi-asserted-by":"crossref","unstructured":"Lin B, He W, Chen Z, Shen M, Shou X, Chen L et al (2023) Self-reported symptoms in patients with acromegaly: a 6-month follow-up in a single neurosurgical center. Endocr J 70(1):77\u201387","DOI":"10.1507\/endocrj.EJ22-0241"},{"key":"1022_CR172","doi-asserted-by":"crossref","unstructured":"T\u2019Sjoen G, Bex M, Maiter D, Velkeniers B, Abs R (2007 Oct) Health-related quality of life in acromegalic subjects: data from AcroBel, the Belgian registry on acromegaly. Eur J Endocrinol [Internet]. 157(4):411\u2013417. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/17893254\/. cited 2024 Jan 7","DOI":"10.1530\/EJE-07-0356"},{"issue":"3","key":"1022_CR173","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1027\/\/1015-5759.18.3.242","volume":"18","author":"U Scholz","year":"2002","unstructured":"Scholz U, Do\u00f1a BG, Shonali S, Schwarzer R (2002) Is general self-efficacy a universal construct? Psychometric findings from 25 countries. Eur J Psychological Assess 18(3):242\u2013251","journal-title":"Eur J Psychological Assess"},{"key":"1022_CR174","doi-asserted-by":"crossref","unstructured":"Spinhoven P, Ormel J, Sloekers PPA, Kempen GIJM, Speckens AEM, Van Hemert AM (1997 Mar) A validation study of the hospital anxiety and depression scale (HADS) in different groups of Dutch subjects. Psychol Med [Internet]. 27(2):363\u2013370. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/9089829\/. cited 2024 Jan 7","DOI":"10.1017\/S0033291796004382"},{"key":"1022_CR175","doi-asserted-by":"publisher","unstructured":"Valko PO, Bassetti CL, Bloch KE, Held U, Baumann CR (2008 Nov 11) Validation of the fatigue severity scale in a Swiss cohort. Sleep [Internet]. 31(11):1601. Available from: https:\/\/doi.org\/10.1093\/sleep\/31.11.1601. cited 2024 Jan 7","DOI":"10.1093\/sleep\/31.11.1601"},{"key":"1022_CR176","doi-asserted-by":"publisher","unstructured":"Kendell RE (2006 Apr 1) Diagnostic and statistical manual of mental disorders, 3rd ed., revised (DSM-III-R) [Internet]. 145(10):1301\u20131302. https:\/\/doi.org\/10.1176\/ajp.145.10.1301. cited 2024 Jan 7. Available from: https:\/\/ajp.psychiatryonline.org\/doi\/10.1176\/ajp.145.10.1301","DOI":"10.1176\/ajp.145.10.1301"},{"issue":"5","key":"1022_CR177","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1210\/clinem\/dgab874","volume":"107","author":"M Van Der Meulen","year":"2022","unstructured":"Van Der Meulen M, Zamanipoor Najafabadi AH, Broersen LHA, Schoones JW, Pereira AM, Van Furth WR et al (2022 May 1) State of the art of patient-reported outcomes in acromegaly or GH deficiency: a systematic review and meta-analysis. J Clin Endocrinol Metab 107(5):1225\u20131238","journal-title":"J Clin Endocrinol Metab"},{"key":"1022_CR178","doi-asserted-by":"crossref","unstructured":"Giustina A, Barkan A, Beckers A, Biermasz N, Biller BMK, Boguszewski C et al (2020 Apr 1) A consensus on the diagnosis and treatment of acromegaly comorbidities: an update. J Clin Endocrinol Metab [Internet]. 105(4):E937\u201346. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/31606735\/. cited 2024 Jan 26","DOI":"10.1210\/clinem\/dgz096"}],"container-title":["Journal of Patient-Reported Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41687-026-01022-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41687-026-01022-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41687-026-01022-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T23:39:26Z","timestamp":1784072366000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s41687-026-01022-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,11]]},"references-count":178,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1022"],"URL":"https:\/\/doi.org\/10.1186\/s41687-026-01022-3","relation":{},"ISSN":["2509-8020"],"issn-type":[{"value":"2509-8020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,11]]},"assertion":[{"value":"12 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"No informed consent or Institutional Review Board approval was needed due to the nature of this research.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors approved the final version of this manuscript and its publication.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Jorge E. Contreras-Saldarriaga has received speaker fees from Ipsen. Carlos E. Builes-Monta\u00f1o has received consulting or speaker fees from Sanofi, Novo Nordisk, Novartis, Recordati Rare Diseases, Amgen, Ipsen and Boehringer Ingelheim. The other authors certify that they have no affiliation nor are they involved with any organization or entity with any financial interest (such as fees, financial aid for education, shares, employment contracts, work as consultants, or any other type of interest) or non-financial interest (such as personal, professional relationships, affiliations, or beliefs) in the topic of interest or any material discussed in this manuscript.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"119"}}